Latest Headlines
Stereotactic radiation controls early stage lung cancer
Melanoma survivors at higher risk of other cancers
Cladribine and fludarabine equally helpful for progressive CLL
More frequent surveillance reduces colon cancer risk in Lynch syndrome families
Radiation can be avoided in early Hodgkin's lymphoma
NEWS PROVIDED BY 
VIEW ALL NEWSDocetaxel better than doxorubicin in early breast cancer
NEW YORK (Reuters Health) - In women with early-stage breast cancer, treatment with docetaxel with cyclophosphamide (TC) achieved a greater overall survival benefit than doxorubicin and cyclophosphamide (AC), researchers report in a February 9th on-line publication in the Journal of Clinical Oncology.
"Long-term follow-up of the TC regimen," lead investigator Dr. Stephen Jones told Reuters Health, "confirms its superiority over a standard anthracycline-based regimen and offers women a regimen with less potential long-term toxicity involving the bone marrow and heart."
Dr. Jones, of US Oncology Research, Dallas, Texas, and colleagues studied 1016 women who had been randomized to receive infusions of TC (75/600 mg/m�) or AC (60/600 mg/m�) every 3 weeks for 4 cycles.
With a median follow-up of 7 years, disease-free survival in the TC group was 81%, significantly greater than the 75% seen in the AC patients. Overall survival was also significantly greater with TC (87% versus 82%).
"There was no interaction of hormone receptor status or HER-2 status and treatment," the authors said.
Given the findings overall, concluded Dr. Jones, "Many women worldwide can now be safely treated with an effective non-anthracycline regimen."
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 